Inici › Limfoma › Ohio › Cleveland
Assaigs clínics de Limfoma a Cleveland, OH
14 estudis de Limfoma busquen participants en centres de Cleveland i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
ReclutantFase 1/2
- University Hospitals Seidman Cancer Center, Cleveland
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
ReclutantFase 1
- University Hospitals Cleveland Medical Center, Cleveland
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
ReclutantFase 2
- Cleveland Clinic, Cleveland
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
ReclutantFase 2
- University Hospitals Cleveland Medical Center, Cleveland
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
ReclutantFase 2
- The Cleveland Clinic Foundation, Cleveland
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
ReclutantFase 3
- Research Site, Cleveland
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
ReclutantFase 1/2
- Cleveland Clinic, Cleveland
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
ReclutantFase 1/2
- Cleveland Clinic, Cleveland
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
ReclutantFase 3
- Cleveland Clinical Taussig Cancer Center, Cleveland
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
ReclutantFase 1
- University Hospitals Cleveland Medical Center, Cleveland
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutantFase 1
- Cleveland Clinic, Cleveland
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
ReclutantFase 1/2
- Cleveland Clinic, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Cleveland Clinic, Cleveland
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
ReclutantFase 1
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Assaigs de Limfoma en altres ciutats
- Houston, TX34 estudis
- Boston, MA33 estudis
- New York City, NY33 estudis
- Washington, DC23 estudis
- Baldwin Park, CA21 estudis
- Chicago, IL20 estudis
- Durham, NC17 estudis
- St. Louis, MO15 estudis
- Philadelphia, PA15 estudis
- Edison, NJ12 estudis
- Atlanta, GA12 estudis
- Seattle, WA12 estudis
Altres estudis a Cleveland
- Càncer de pulmó de cèl·lules no petites43 estudis
- Càncer (tots els tipus)36 estudis
- Càncer de mama35 estudis
- Càncer de pròstata34 estudis
- Insuficiència cardíaca33 estudis
- Càncer metastàtic30 estudis
- Càncer d'ovari30 estudis
- Càncer de pulmó26 estudis
- Càncer colorrectal24 estudis
- Malaltia cardiovascular22 estudis
- Càncer d'endometri20 estudis
- Leucèmia mieloide aguda20 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.